Literature DB >> 12181114

The effect of interleukin-6 on L-selectin levels on polymorphonuclear leukocytes.

Tatsushi Suwa1, James C Hogg, Kevin B Quinlan, Stephan F Van Eeden.   

Abstract

Interleukin-6 (IL-6) shortens the transit time of polymorphonuclear leukocytes (PMN) through the marrow and accelerates their release into the circulation. In contrast to other inflammatory stimuli, this response is associated with a decrease in L-selectin levels on circulating PMN. The present study was designed to determine the effect of IL-6 on L-selectin levels of PMN in rabbits. Recombinant human IL-6 (2 microg/kg) caused a decrease in L-selectin levels on circulating PMN 3 to 12 h after treatment (P < 0.05). L-selectin levels decreased on PMN already in the circulation for up to 4 h (P < 0.05), on PMN released from the marrow posttreatment for up to 12 h (P < 0.01) and on PMN in the marrow for up to 6 h (P < 0.05) after IL-6 treatment. We conclude that IL-6 decreases L-selectin levels on circulating PMN by demarginating PMN with low levels of L-selectin and by releasing PMN from the marrow with low levels of L-selectin. We postulate that this prolonged downregulation of L-selectin on circulating PMN could influence their recruitment into inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181114     DOI: 10.1152/ajpheart.00185.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  9 in total

1.  Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury.

Authors:  Ozlem U Gurkan; Chaoxia He; Rachel Zielinski; Hamid Rabb; Landon S King; Jeffrey M Dodd-o; Franco R D'Alessio; Neil Aggarwal; David Pearse; Patrice M Becker
Journal:  Exp Lung Res       Date:  2011-11-01       Impact factor: 2.459

Review 2.  Pertussis leukocytosis: mechanisms, clinical relevance and treatment.

Authors:  Nicholas H Carbonetti
Journal:  Pathog Dis       Date:  2016-09-07       Impact factor: 3.166

3.  Disentangling the effects of tocilizumab on neutrophil survival and function.

Authors:  Timo Gaber; Martin Hahne; Cindy Strehl; Paula Hoff; Yvonne Dörffel; Eugen Feist; Gerd-Rüdiger Burmester; Frank Buttgereit
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

4.  Novel properties of statins: suppression of the systemic and bone marrow responses induced by exposure to ambient particulate matter (PM(10)) air pollution.

Authors:  Ryohei Miyata; Ni Bai; Renaud Vincent; Don D Sin; Stephan F Van Eeden
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-13       Impact factor: 5.464

5.  Prognostic potential of pre-partum blood biochemical and immune variables for postpartum mastitis risk in dairy cows.

Authors:  Ruo-Wei Guan; Di-Ming Wang; Bei-Bei Wang; Lu-Yi Jiang; Jian-Xin Liu
Journal:  BMC Vet Res       Date:  2020-05-14       Impact factor: 2.741

Review 6.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

7.  Biochemical, pharmacological, and structural characterization of new basic PLA2 Bbil-TX from Bothriopsis bilineata snake venom.

Authors:  Victor Corasolla Carregari; Rafael Stuani Floriano; Lea Rodrigues-Simioni; Flavia V Winck; Paulo Aparecido Baldasso; Luis Alberto Ponce-Soto; Sergio Marangoni
Journal:  Biomed Res Int       Date:  2012-12-30       Impact factor: 3.411

8.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Authors:  P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

9.  Differential CpG DNA methylation in peripheral naïve CD4+ T-cells in early rheumatoid arthritis patients.

Authors:  R Pitaksalee; A N Burska; S Ajaib; J Rogers; R Parmar; K Mydlova; X Xie; A Droop; J S Nijjar; P Chambers; P Emery; R Hodgett; I B McInnes; F Ponchel
Journal:  Clin Epigenetics       Date:  2020-04-07       Impact factor: 6.551

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.